0001213900-23-039907.txt : 20230515 0001213900-23-039907.hdr.sgml : 20230515 20230515170114 ACCESSION NUMBER: 0001213900-23-039907 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230508 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vivo Opportunity, LLC CENTRAL INDEX KEY: 0001728970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 23923970 BUSINESS ADDRESS: STREET 1: 192 LYTTON AVENUE CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: 6506880818 MAIL ADDRESS: STREET 1: 192 LYTTON AVENUE CITY: PALO ALTO STATE: CA ZIP: 94301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vivo Opportunity Fund Holdings, L.P. CENTRAL INDEX KEY: 0001930214 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 23923969 BUSINESS ADDRESS: STREET 1: 192 LYTTON AVENUE CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: 6506880818 MAIL ADDRESS: STREET 1: 192 LYTTON AVENUE CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 REDWOOD SHORES PARKWAY STREET 2: SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 203 REDWOOD SHORES PARKWAY STREET 2: SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 3 1 ownership.xml X0206 3 2023-05-08 0 0001484565 SOLENO THERAPEUTICS INC SLNO 0001728970 Vivo Opportunity, LLC 192 LYTTON AVENUE PALO ALTO, CA 94301 0 0 1 0 0001930214 Vivo Opportunity Fund Holdings, L.P. 192 LYTTON AVENUE PALO ALTO, CA 94301 0 0 1 0 Tranche A Warrants (right to buy) 1.75 Common Stock 3203093 I By Vivo Opportunity Fund Holdings, L.P. Tranche B Warrants (right to buy) 2.50 Common Stock 5215000 I By Vivo Opportunity Fund Holdings, L.P. The Tranche A Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS). Notwithstanding the foregoing, the exercise of such Warrants is subject to a 19.99% beneficial ownership blocking provision, which will terminate upon approval of the Issuer's stockholders of the issuance of shares underlying such Warrants. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The Tranche B Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days following receipt of Food and Drug Administration's marketing approval of DCCR for the treatment of PWS. Notwithstanding the foregoing, the exercise of such Warrants is subject to a 19.99% beneficial ownership blocking provision, which will terminate upon approval of the Issuer's stockholders of the issuance of shares underlying such Warrants. VIVO OPPORTUNITY, LLC, By: /s/ Gaurav Aggarwal 2023-05-15 VIVO OPPORTUNITY FUND HOLDINGS, L.P, By: Vivo Opportunity, LLC, its general partner, By: /s/ Gaurav Aggarwal 2023-05-15